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Abstract
Background—In Sub-Saharan Africa, prevalence estimates of hepatitis C virus (HCV) vary
widely.
Objectives—To assess the prevalence of HCV infection among HIV-infected, pregnant women
screened for a large clinical trial in Lilongwe, Malawi.
Study design—Plasma from 2041 HIV-infected, pregnant women was screened for anti-HCV
IgG using a chemiluminiscent immunometric assay (CIA). Specimens with a signal-cut-off ratio ≥
1.00 were considered reactive and those with S/Co ratio < 1.00 non-reactive. All CIA-reactive
specimens were tested by a recombinant immunoblot assay (RIBA) for anti-HCV and by PCR for
HCV RNA.
Results—Of 2041 specimens, 110 (5.3%, 95% CI: 4.5–6.5%) were CIA reactive. Of the 109
CIA reactive specimens available for RIBA testing, 2 (1.8%) were positive, 28 (25.7%) were
indeterminate, and 79 (72.5%) were negative. All CIA-reactive specimens were HCV RNA
negative (n = 110). The estimated HCV prevalence based on the screening assay alone was 5.3%;
based on supplemental RIBA testing, the status of HCV infection remained indeterminate in 1.4%
(28/2040, 95% CI: 0.1–2.0) and the prevalence of confirmed HCV infections was 0.1% (2/2040,
95% CI: 0–0.4%).
☆The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the
Centers for Disease Control and Prevention.
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Conclusions—HCV seroprevalence among HIV-infected, pregnant women in Malawi
confirmed by supplemental RIBA HCV 3.0 is low (0.1%); CIA showed a high false-reactivity rate
in this population.
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1. Background
Worldwide, approximately 170 million are infected with hepatitis C virus (HCV); 40 million
are infected with human immunodeficiency virus type-1 (HIV); and, 4.5 million are infected
with both viruses.1,2 Co-infection with HCV and HIV is of particular concern in Sub-
Saharan Africa.3 In Malawi, the estimated prevalence of HCV infection varies widely (0.7–
16.5%) by subpopulation and whether supplemental testing confirmed screening results.5–10
The only study to date among HIV-infected, pregnant women in Malawi estimated the
prevalence of non-confirmed, anti-HCV positivity at 16.5%.4 Only one study in Malawi
employed both serologic and supplemental nucleic acid testing for HCV infection, and it
reported that only one in 10 HCV screening positive samples was positive for HCV
ribonucleic acid (RNA).7 With the high prevalence of HIV-infection and increasing access
to life-prolonging, antiretroviral therapy in Sub-Saharan Africa, liver disease is emerging as
a major cause of morbidity and mortality among HIV-infected persons, particularly those
co-infected with hepatitis.10,11 It is imperative that we understand the limitations of the
current assays for detection of HCV infection and more accurately estimate the prevalence
of HCV and HIV co-infection.
2. Objectives
The objective was to assess the prevalence of HCV infection using screening and
supplemental confirmatory testing among HIV-infected, pregnant women being screened for
a large clinical trial in Lilongwe, Malawi.
3. Study design
We analysed plasma specimens from 2041 antiretroviral-naive, HIV-infected, pregnant (<30
weeks gestation) women collected at pre-inclusion screening for the Breastfeeding,
Antiretrovirals, and Nutrition (BAN) Study (www.TheBANStudy.org).12,13 The study was
approved by the Malawi National Health Sciences Research Committee and institutional
review boards at the University of North Carolina at Chapel Hill and the U.S. Centers for
Disease Control and Prevention (CDC) in Atlanta, GA. All women provided written,
informed consent for specimen storage and future laboratory studies. Specimens were
shipped from −80 °C storage in Lilongwe (Malawi) to CDC for testing. All specimens were
tested for anti-HCV IgG using a chemiluminescent immunoassay (CIA) (VITROS aHCV;
Ortho-Clinical Diagnostics, Inc., Rochester, NY) according to manufacturer’s instructions.
Specimens with a signal-to-cutoff (S/Co) ratio ≥ 1.00 were considered reactive, whereas
those with an S/Co < 1.00 were considered non-reactive. All CIA-reactive specimens
underwent supplemental testing with a recombinant immunoblot assay (RIBA) (RIBA HCV
3.0 SIA; Novartis Inc., New York, NY) and PCR for HCV RNA by a qualitative assay
(COBAS AMPLICOR HCV Test v2.0; Roche Molecular Diagnostics, Indianapolis, IN).
Using CDC guidelines,14 a specimen was considered (i) anti-HCV negative if it was CIA
non-reactive or RIBA negative; (ii) anti-HCV positive if CIA-reactive and RIBA or HCV
RNA positive; (iii) furthermore, since there was no possibility to collect a sample for repeat
anti-HCV or HCV RNA testing after >1 month all specimens that were CIA-reactive with an
indeterminate RIBA and negative HCV RNA result were considered anti-HCV
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indeterminate. Also according to CDC testing guidelines, specimens with a CIA S/Co ratio
of >8.0 (established for Ortho HCV CIA) can be considered HCV positive without
supplemental testing,14 and we evaluated the utility of this cut-off for predicting positive
RIBA and HCV RNA results in this population. HCV prevalence was estimated using
binomial exact methods.
4. Results
The women had a median age of 25 (interquartile range (IQR): 22–29, range: 14–45) years,
CD4 count of 425 (IQR: 300–571, range: 100–1218) cells/mm3, and alanine
aminotransferase (ALT) level of 13 (IQR: 10–15, range: 2–74) IU/L. Overall, the population
was of low socioeconomic status, as indicated by a low percentage (18%) with electricity in
the home.
Of 2041 specimens, 110 (5.4%, 95% CI: 4.5–6.5%) were CIA reactive (Fig. 1); 98 had S/Co
≤ 8.0, and 12 had S/Co > 8.0. Of the 98 with a S/Co ≤ 8.0, 97 were tested by RIBA; 1 had
insufficient volume and was excluded from further analysis. Of the 97, 1 (1.0%) was
positive, 27 (27.8%) were indeterminate, and 69 (71.1%) were negative by RIBA; all were
HCV RNA negative. Of the 12 samples with S/Co ≤ 8.0, 1 (8.3%) was positive, 1 (8.3%)
was indeterminate, and 10 (83.3%) were negative by RIBA; all were HCV RNA negative.
The two specimens that tested RIBA positive had CIA S/Co ratios of 15.5 and 4.6.
Therefore, a CIA S/Co > 8.0 did not correlate with RIBA and HCV RNA PCR positivity in
this population.
Overall, of the 109 CIA reactive specimens tested by RIBA, 2 (1.8%) were positive, 28
(25.7%) were indeterminate, and 79 (72.5%) were negative. None of the CIA-reactive
specimens tested positive for HCV RNA. The two women who were RIBA positive had a
significantly higher median ALT level (29 IU/L) compared to women with indeterminate
(12 IU/L) or negative (13 IU/L) RIBA results (p = 0.02).
The RIBA confirmed anti-HCV prevalence among these HIV-infected pregnant women in
Malawi was 0.1% (2/2040, 95% CI: 0–0.4%), while 1.4% of participants had anti-HCV
indeterminate results. Among the 81 women with reactive CIA and determinate RIBA
results, the positive predictive value (PPV) of the CIA for RIBA reactivity was 2.5% (2 of
81, 95% CI: 0.8–8.5%) and the false-positive rate was 97.5% (79 of 81, 95% CI: 91.5–
99.2%). The specificity of the CIA assay for evidence of HCV infection among women in
this study is uncertain since CIA-non-reactive specimens were not tested by RIBA or HCV
RNA. However, following CDC guidelines, we considered CIA-non-reactive specimens (n =
1931) anti-HCV negative and excluded the 28 indeterminate results from the denominator
(2040) to estimate the CIA specificity at 96.0% (1931/2012, 95% CI: 95.0–96.8%).
5. Discussion
The prevalence of HCV was 5.3% by CIA and 0.1% by supplemental RIBA among this
population of HIV-infected, pregnant women in Malawi. The only other study in Malawi
that used supplementary testing with RIBA and HCV RNA reported a HCV prevalence of
6.8% by CIA and 0.7% by confirmed HCV RNA among blood donors.7 These estimates of
HCV prevalence in Malawi are consistent with other studies in Sub-Saharan Africa that used
supplemental testing.4,15–17 Together these studies indicate that most HCV prevalence
estimates from Sub-Saharan Africa based on screening assays are overestimated. Continued
HCV screening without supplemental confirmatory testing of blood donations would result
in discarding uninfected blood, and the disclosure of test results may cause unnecessary
despair to those misdiagnosed and the permanent withdrawal of uninfected donors from the
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small donor pool. Future efforts should focus on improving the HCV testing algorithm in
Sub-Saharan Africa.
Our data does not support the use of a CIA S/Co ratio ≥ 8.0 for Vitros CIA to screen for
HCV infection among HIV-infected, pregnant women in Malawi. Current CDC HCV testing
guidelines suggest that CIA-reactive samples with a S/Co ratio ≥ 8.0 for Vitros CIA may be
reported as anti-HCV positive without further supplemental testing.14 Although this
criterion would reduce screening costs, our study indicates that in such low prevalence
settings, S/Co ratio thresholds established for various assays would result in false-positive
results and may not reflect true HCV infections.
Our study had some limitations. The number of CIA reactive specimens that gave
indeterminate RIBA results was high, but this observation has been noted elsewhere in
settings of low HCV seroprevalence16; to determine HCV status in persons with such results
another sample should be collected for repeat anti-HCV or for HCV RNA testing > 1 month
later. Intermittent viremia is known to occur in HCV infection,14 which could lead to a
negative single HCV RNA test. The CDC guidelines are based on studies conducted among
different populations in the United States and thus may not be fully applicable to the
population of HIV-infected, pregnant women in Malawi. Furthermore, the main BAN trial
was not designed to answer questions about HCV and lacks data on history of blood
transfusion and injection drug use, which are rare in Malawi.
In conclusion, HCV seroprevalence among HIV-infected, pregnant women in Malawi is low
when confirmed by supplemental RIBA HCV 3.0. The CIA showed a high false-reactivity
rate. Given the high cost of supplemental testing by RIBA and nucleic acid tests, there is a
need to evaluate the performance of available anti-HCV assays (including available rapid
tests) in various populations in Malawi and other African settings, including the general
population, blood donors, and risk groups.
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